PIPELINE
OKN-007
What is Glioblastoma Multiforme?
Glioblastoma multiforme is one of the most malignant tumors among all brain tumors. In general, glioblastoma multiforme is treated with radiotherapy and chemotherapy after surgical removal of the tumor, but the prognosis is very poor so it is urgent to develop new treatments.
Development Stage
| Pipeline | Treatment Areas | Indication |
Initial
Development Clinical Trial Phase 1 Clinical Trial Phase 2 Clinical Trial Phase 3 |
|
|---|---|---|---|---|
|
OKN-007
|
Brain Cancer
|
Rare Disease
|
Glioblastoma Multiforme (rGBM)
|
|
|
Glioblastoma Multiforme (rGBM)
|
|
|||
- OKN-007 : Disufenton Sodium, Nitrone derivatives for the treatment of glioblastoma multiforme
- Ongoing Phase 1 clinical trial of the combination therapy with OKN-007 and temozolomide in patients with newly diagnosed glioblastoma multiforme as an investigator
- Completed recruitment of Phase 1b clinical trial to patients with recurrent glioblastoma multiforme using OKN-007
- Designated as an orphan drug for the a treatment of glioblastoma multiforme by the US FDA
- Ongoing Phase 2 clinical trial (combination therapy with OKN-007 and temozolomide)
- Oral Clinical Trial in Progress for Recurrent Patients
